摘要
目的:观察替比夫定与恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者的临床疗效及安全性。方法:将140例慢性乙型肝炎患者随机分为替比夫定治疗组75例,恩替卡韦组治疗组65例,疗程均为72周。观察两组治疗8、12、24、52、72周时ALT复常率、HBVDNA低于检测下限值率、HBeAg血清学转换率及药物的安全性。结果:治疗8、12、24、52、72周时ALT复常率、HBVDNA低于检测下限值率两组比较差异均无统计学意义(均P>0.05);治疗8、12、24周时HBeAg血清学转换率两组比较差异均无统计学意义(均P>0.05);治疗52周及72周时两组HBeAg血清学转换率分别为30.7%和16.9%(P<0.05),36.0%和23.1%(P<0.05)。两组均未发现明显不良反应。结论:替比夫定与恩替卡韦治疗HBeAg阳性慢性乙型肝炎均具有快速强效抗病毒作用,近期ALT复常率、HBVDNA低于检测下限值率、HBeAg血清学转换率均无明显差异,但治疗52、72周时替比夫定组HBeAg血清学转换率高于恩替卡韦组。两药治疗的安全性和耐受性良好。
Objective To evaluate the efficacy and safety of telbivudine versus those of entecavir for patients with HBeAg-positive chronic hepatitis B. Methods 140 patients were randomized to receive telbivudine （75 patients） or entecavir （65 patients） for 72 weeks.Serum ALT normalization rate, rate of undetectable HBV DNA, HBeAg seroconversion rate, and safiy of the two agents were determined at weeks 8, 12, 24, 52, and 72. Results Serum ALT normalization rate and rate of undetectable HBV DNA did not differ significantly between the two groups at weeks 8, 12, 24, 52, and 72 （P〉 0.05）, nor HBeAg seroconversion rate at weeks 8, 12, and 24 （P 〉 0.05）~ HBeAg seroconversion rates was 30.7% in telbivudine group and 16.9% in entecavir group at week 52 （P 〈 0.05）, and 36.0% and 23.1% at week 72 （P 〈 0.05）. No adverse reactions were found in both groups. Conclusions Both telbivudine and entecavir have a rapid, strong antiviral effect on HBeAg-positive chronic hepatitis B. Serum ALT normalization rate, rate of undetectable HBV DNA, and HBeAg seroconversion rate do not differ between the patients receiving telbivudine and those receiving entecavir, but telbivudine has a higher rate of HBeAg scroconvcrsion than entccavir at weeks 52 and 72. Both medications have good safty and tolerance.
出处
《实用医学杂志》
CAS
北大核心
2010年第14期2609-2611,共3页
The Journal of Practical Medicine
基金
广州市卫生局资助项目(编号:2009-YB-087)
广东省科技计划项目(编号:2009B080702034)
